US/UK/Canada

Share

About Us

Inhalation Sciences Sweden AB (publ.) develops and sells patented, highly innovative labtech equipment for inhalation research. Scientists using it can now know, with unprecedented accuracy, how particles behave in our lungs when we inhale them: whether new pollutants or life-saving drugs that power human development.

Pick a time period -
Tags ( Active)

Inhalation Sciences’ launch of the XposeALI[®] in vitro module with microperfusion

(Stockholm, Sweden, 13 January 2025) Inhalation Sciences (ISAB) announces its plans to launch the company’s XposeALI[®] in vitro exposure module, now with microperfusion. The development work was undertaken in 2024 with the final testing and validation being performed in a study co-financed with one of the company’s longstanding global pharmaceutical customers.By adding the option of microperfusion to the XposeALI system, the mode-of-action of inhaled substances in the lungs can now be simulated in vitro with higher relevance. The unique capability of the XposeALI system to deliver various

Inhalation Sciences receives IRS order worth SEK 212,000 from global leader in generics and biosimilars

(Stockholm, Sweden, 10 January 2025) Inhalation Sciences AB (ISAB) has received an order worth SEK 212,000 from a returning client, a global leader in generics and biosimilars, for an Inhalation Research Services (IRS) project.The client has chosen ISAB’s unique technology for a feasibility test and given a positive outcome, additional IRS are being planned. CEO Manoush Masarrat comments: "We are delighted that our technology has been selected by such an expert and experienced team. This is important work, and we look forward to working with this project. We see good potential here for

Inhalation Sciences submits Project Report and Summary Data to the FDA for Final Review

(Stockholm, Sweden, 9 January 2025) Inhalation Sciences Sweden AB (ISAB) is proud to announce the submission of the project report and summary data to the U.S. Food and Drug Administration (FDA) for final review and approval. This marks a key milestone in ISAB’s ongoing FDA BAA (Broad Agency Agreement) Contract 75F40122C00197 for a collaborative research project which evaluates the discriminative dissolution potential of its innovative DissolvIt[®] system for assessing drug formulations designed for inhalation therapy.The DissolvIt[®] system is designed to address a critical need in

Inhalation Sciences receives new orders totalling 33,900 Euro for technical service contracts

(Stockholm, Sweden, 17 December 2024) Inhalation Sciences AB (publ), a world-leading research and development company in the field of inhalation, is pleased to announce the receipt of new orders for technical service contracts, totalling 33,900 Euro, from two recurrent customers in Europe.The contracts were awarded by a major pharmaceutical company and an academic institution. These recurring customers have chosen Inhalation Sciences to ensure the uninterrupted operation of their inhalation research. By providing comprehensive preventative maintenance as part of the service contracts,

Inhalation Sciences AB (publ) releases Q3 Report 2024

(Stockholm, Sweden, 20 November, 2024) Inhalation Sciences AB announces that its Q3 Report for 2024 is now available on the company's website.To read the whole report (in Swedish) visit: http://inhalation.se/investors/finansiella-rapporter/ CEO statement Order intake in the third quarter was higher than in the same period last year, although revenues were slightly lower because of weaker order intake in the January-September reporting period. During the third quarter, we continued our strategy of actively engaging in close dialogue with all customers who have requested quotes, as

Inhalation Sciences provides latest status update on ongoing FDA BAA dissolution research project

(Stockholm, 16 October 2024) Inhalation Sciences Sweden AB (ISAB) today releases the latest update on progress in its FDA BAA (Broad Agency Agreement) dissolution collaborative research project evaluating the discriminative power of ISAB’s DissolvIt[®] in comparing drug formulations aimed for administration via inhalation. The project - contract number 75F40122C00197 - was communicated by ISAB on September 15[th], 2022, with updates throughout 2023.ISAB today announces that the deadline for the formal completion of its FDA BAA project has been extended by six months, with an updated

Publication of positive performance of ISAB’s in vitro module demonstrated in collaboration with Karolinska Institutet

A new publication demonstrates how XposeALI[®], Inhalation Sciences’ in vitro cell-based exposure module, successfully predicted the toxicity of inhaled palladium nanoparticles, an emerging pollutant from motor vehicles, in the lung lining. The study was carried out, and the paper co-authored, by scientists from Karolinska Institutet and the Swedish University of Agricultural Sciences as well as Inhalation Sciences. The paper is published in Frontiers in Medicine (Pulmonary Medicine section).Palladium nanoparticle (Pd-NP) emissions from catalytic converters are emerging as a potential

Inhalation Sciences AB (publ) releases Q2 Report 2024

(Stockholm, Sweden, 28 August 2024) Inhalation Sciences AB announces that its Q2 Report for 2024 is now available on the company’s website.To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/ CEO statement Our journey towards achieving the company's strategic goals has continued during the second quarter. We have worked purposefully towards a positive cash flow, which has yielded results in the form of an improved operating profit of 24% by the first half of 2024, compared to the same period the year before. Our pipeline in the form of

Surge of new orders totalling 50,000 Euro signals new sales season for Inhalation Research Services

(Stockholm, 15 August 2024) Inhalation Sciences AB (ISAB) has received a surge of new orders, primarily for its Inhalation Research Services, as the summer season comes to a close and the company and wider inhalation industry gear up for a busy second half of the year.The combined value of the new orders totals 50,000 Euro, or 600,000 SEK. The orders have been received from returning clients in ISAB’s extensive portfolio, primarily for CRO projects by its Inhaled Research Services team. ISAB CEO Manoush Masarrat: “we are pleased to see clients hit the ground running again following the

Forthcoming changes in Inhalation Sciences’ Board of Directors

Inhalation Sciences Sweden AB’s (publ) (“Inhalation Sciences” or the “Company”) Nomination Committee proposes that Ulf Ericsson be elected as new Board member.The Company intends to convene an Extraordinary General Meeting where the Nomination Committee proposes that Ulf Ericsson be elected as a new Board member. “The Inhalation Science’s Board is very excited about the nomination of Ulf as a new Board member in the company. Given Ulf’s long experience and deep understanding of the inhalation research market as well as good insights into the needs and requirements of our customers, he

Inhalation Sciences receives new IRS order for DissolvIt® study worth 57,000 Euro from leading inhalation big pharma

(Stockholm, 13 June 2024) Inhalation Sciences AB (ISAB) has received its first order for a preclinical dissolution study using its high-precision DissolvIt® technology from a returning customer who is one of the world’s top 10 big pharma companies developing inhaled pharmaceuticals. The order is worth 57,000 EURO - over 600,000 SEK.This is the first time the long-term client has requested a preclinical dissolution study from ISAB, having previously carried out such studies using in-house technology. The new study will use DissolvIt® - ISAB’s unique, highly sensitive dissolution testing

Watch ISAB CEO go behind the headlines in high-value Q1 interview

Inhalation Sciences CEO Manoush Masarrat discusses the company’s recent Q1 Report, and takes investors’ questions, in the first of a new regular series.Watch the interview here . Together with analyst Jonathan Furelid ISAB’s CEO analyzes the Company’s recent Q1 results, taking investor’s questions and adding significant business intelligence and insights. The interview is the first in a series of Quarterly videos that will run through 2024.

Inhalation Sciences AB (publ) releases Q1 Report 2024

(Stockholm, Sweden, 28 May 2024) Inhalation Sciences AB announces that its Q1 Report for 2024 is now available on the company’s website.To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/ CEO statement Our first quarter started out strong with an increased revenue of 17% compared to the same period the year before. We also have a continued improved operating profit through continuous cost control and a streamlined organization that is designed to reach profitability in the near term and deliver growth according to our plan. Through

Inhalation Sciences presents at well-received FDA public workshop GDUFA

On 20 May Inhalation Sciences AB CSO Per Gerde presented the company’s predictive tools for developing and assessing generic inhaled pharmaceuticals at the FDA’s public GDUFA (Generic Drug User Fee Amendments) webinar (as previously communicated on April 10, 2024). The webinar was well-attended and well-received by a large audience of specialist industry professionals.ISAB’s webinar session at the workshop was titled “Predictive Tools for Generic Product Development & Assessment”. It was held by ISAB CSO and Founder Per Gerde and ISAB’s Director of Projects Dr Maria Malmlöf. Engagement

Inhalation Sciences receives new order worth 60,000 Euro from long-term big pharma client

Inhalation Sciences AB (ISAB) has received a purchase order worth 60,000 EURO (almost 700,000 SEK) from a returning customer – one of the world’s top five generics companies by revenue. The client uses an ISAB PreciseInhale® aerosol generation system in-house as a central part of its R&D on inhaled pharmaceuticals.The order is for essential spare parts and consumables for the client’s PreciseInhale® system. The client is a long-term customer of ISAB’s with a world-class generics pipeline and robust R&D organisation. Prior to its purchase and installation of PreciseInhale® the client carried

Inhalation Sciences AB (publ) releases Annual Report 2023

Inhalation Sciences AB announces that its Annual Report for 2023 is now available on the company’s website.To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/ CEO comments 2023 was another year in which we continued to take new market share and successfully deliver on our strategic goals. Over the past three years, revenue has increased steadily by 29% from 2021 to 2022 and now by 44% from 2022 to 2023. At the same time, we have also significantly improved our operating profit during the same period. With this positive development, we

Inhalation Sciences to present at FDA’s public workshop GDUFA on May 20th, 2024

Inhalation Sciences Sweden AB (ISAB) has been invited to provide a public comments presentation at the FDA’s public workshop GDUFA (Generic Drug User Fee Amendments) on May 20[th], 2024.The annual GDUFA Public Workshop is open and free to the public, and any member of the public may provide comments to the docket for the meeting or may provide their public comments in a prepared presentation, or as impromptu comments. The FDA routinely announces the workshop and provides information about how the public may provide comments. This includes information about how the public can submit a

Positive results of first-in-human clinical trial of PreciseInhale now published in European Journal of Pharmaceutical Sciences

(Stockholm, 11 March 2024) Positive results from Inhalation Sciences’ first-in-human clinical study of its aerosol generating system PreciseInhale® are now published in a peer-reviewed paper in the European Journal of Pharmaceutical Sciences. The results demonstrate that PreciseInhale® provides greater precision and control than aerosol dosing carried out with a standard commercial inhaler, and can be used for ‘regional targeting’, exposing specific regions of the lungs to a targeted aerosol. The topline results were first communicated on December 20, 2021.The paper is titled Regional lung

Inhalation Sciences AB (publ) releases Q4 / YE Report

(Stockholm, Sweden, 28 February 2024) Inhalation Sciences AB announces that its Q4 / Year End Report for 2023 is now available on the company’s website.To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/ CEO statement 2023 was another year when we continued to capture new market shares and successfully deliver on our strategic goals. Over the past three years, revenue has increased steadily by 29% from 2021 to 2022 and now by 49% from 2022 to 2023. At the same time, we have also significantly improved our operating profit at a similar

Inhalation Sciences signs new partnership with Actarmo Medical: End-to-end offering for respiratory drug development Services

Inhalation Sciences AB (ISAB) has signed a new partnership with fellow European inhalation development service provider Actarmo Medical GmbH based in Germany. The new partnership is expected to enlarge the service scope and offerings to the client pipelines of both companies. ISAB and Actarmo have highly complementary services at either end of the respiratory drug development chain, in the fast-growing inhaled therapeutics market.Inhalation Sciences AB has entered a new partnership with Actarmo Medical GmbH, a respiratory drug development services provider headquartered in Gauting, Germany.

Inhalation Sciences secures product service contract worth 47,000 Euro

(Stockholm, Sweden, 29 December,2023) Inhalation Sciences AB (ISAB) has secured a product service contract with a worth of 47,000 Euro on its instruments at the facilities of a large European pharma company. The order reaffirms the client’s strong commitment to its continuing use of ISAB instruments on their robust portfolio of inhaled therapies.The client is a long-standing ISAB customer. Its suite of in-house ISAB instruments has played an important role in developing its competitive and substantial pipeline of inhaled therapeutics. The new contract will cover the service and maintenance

Inhalation Sciences’ captures interest and interaction at its latest industry webinar ‘Inhaled Biologics’

(Stockholm, Sweden, 13 December 2023) Interest and interaction was high on December 11 at ISAB’s latest industry webinar, ‘Inhaled Biologics’. Over 200 scientists registered for the event, the latest in ISAB’s highly popular series, with attendees logging in from Europe, Asia and the US. The webinar was co-hosted by experts in the formulation and drying of biologics, Ziccum AB.On December 11 at 11AM EST ISAB held the latest in its popular series of co-hosted industry webinars. The series has become a regular fixture for many scientists working in inhaled therapeutics and drug development,

Inhalation Sciences AB (publ) releases Q3 Report 2023

(Stockholm, Sweden, 29 August,2023) Inhalation Sciences AB announces that its Q3 Report for 2023 is now available on the company’s website.To read the whole report (in Swedish) visit: http://inhalation.se/investors/finansiella-rapporter/ CEO statement Q3 is the third quarter in a row where we have shown continued revenue growth compared to the same period last year. With this outcome, in Q3 we have already exceeded our revenue figures for the full year 2022. It is of course very gratifying, and clearly shows that our adopted strategy, targeted sales efforts and customers' increased

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe